Phase II, Multicenter, Randomized Trial of Docetaxel plus Prednisone with or Without Cediranib in Men with Chemotherapy‐Naive Metastatic Castrate‐Resistant Prostate Cancer

LESSONS LEARNED. The negative results are consistent with the negative results of large phase III trials in which docetaxel plus antiangiogenic agents were used in patients with metastatic castrate‐resistant prostate cancer (mCRPC). The negative data underscore that, despite a sound biological ratio...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Oncologist
Päätekijät: Heath, Elisabeth, Heilbrun, Lance, Mannuel, Heather, Liu, Glenn, Lara, Primo, Monk, J. Paul, Flaig, Thomas, Zurita, Amado, Mack, Philip, Vaishampayan, Ulka, Stella, Philip, Smith, Daryn, Bolton, Susan, Hussain, Arif, Al‐Janadi, Anas, Silbiger, Daniel, Usman, Muhammad, Ivy, S. Percy
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: John Wiley & Sons, Inc. 2019
Aiheet:
Clinical Trial Results
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC6738301/
https://ncbi.nlm.nih.gov/pubmed/31152080
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2019-0331
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia